NASDAQ:KDNY • US16961L1061
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHINOOK THERAPEUTICS INC (KDNY).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-08-01 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2023-06-21 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2023-06-14 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2023-06-13 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-06-13 | Stifel | Downgrade | Buy -> Hold |
| 2023-06-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-06-12 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-06-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-06-12 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-05-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-10 | Wedbush | Reiterate | Outperform |
| 2023-05-02 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-05-02 | Guggenheim | Maintains | Buy |
| 2023-03-06 | Piper Sandler | Initiate | Overweight |
| 2023-03-01 | Guggenheim | Initiate | Buy |
| 2023-02-28 | Oppenheimer | Maintains | Outperform |
| 2023-02-28 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-21 | Oppenheimer | Maintains | Outperform |
| 2022-12-22 | Stifel | Maintains | Buy |
| 2022-12-05 | Wells Fargo | Initiate | Overweight |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-06-28 | Stifel | Initiate | Buy |
| 2022-05-23 | SVB Leerink | Maintains | Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 830K -95.19% | 51.625M 6,119.88% | 6.128M -88.13% | 2.897M -52.73% | 13.277M 358.30% | 81.114M 510.94% | 192.59M 137.43% | 401.71M 108.58% | 688.21M 71.32% | 1.144B 66.23% | 1.761B 53.93% | |
| EBITDA YoY % growth | -53.31M 32.54% | -101.513M -90.42% | -179.984M -77.30% | -224.975M -25.00% | -275.066M -22.26% | -300.294M -9.17% | -51.771M 82.76% | 191.31M 469.53% | 401.69M 109.97% | 740.53M 84.35% | 1.248B 68.53% | |
| EBIT YoY % growth | -54.71M 34.81% | -106.265M -94.23% | -185.083M -74.17% | -246.708M -33.30% | -288.259M -16.84% | -259.447M 10.00% | -142.936M 44.91% | 4.165M 102.91% | 177.47M 4,160.98% | 663.14M 273.66% | 1.167B 75.98% | |
| Operating Margin | -6,591.57% | -205.84% | -3,020.28% | -8,515.97% | -2,171.11% | -319.86% | -74.22% | 1.04% | 25.79% | 57.97% | 66.27% | |
| EPS YoY % growth | -3.64 24.17% | -2.57 29.40% | -2.88 -12.06% | -3.27 -13.68% | -3.52 -7.52% | -2.83 19.56% | -1.52 46.24% | 0.59 138.53% | 3.72 533.62% | 7.94 113.73% | 13.82 74.06% |
All data in USD
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.83 0.26% | -0.79 12.37% | -0.80 5.56% | -0.84 10.26% | -0.87 -5.04% | -0.97 -23.58% | -0.78 3.43% | -0.78 8.10% | -0.74 14.37% | -0.69 28.83% |
| Revenue Q2Q % growth | 255K -89.80% | 272.544K -46.77% | -100.00% | -100.00% | -100.00% | 19.584M 7,085.63% | 2.059M | 4.12M | 10.299M | 16.479M -15.85% |
| EBITDA Q2Q % growth | -49.213M 8.61% | -49.962M 8.84% | -53.407M 11.16% | -58.797M 15.29% | -64.187M -30.43% | -67.537M -35.18% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -61.52M -6.66% | -63.123M -5.37% | -64.52M -5.05% | -68.227M 6.06% | -72.792M -18.32% | -84.22M -33.42% | N/A | N/A | N/A | N/A |
All data in USD
17 analysts have analysed KDNY and the average price target is 41.11 USD. This implies a price increase of 1.77% is expected in the next year compared to the current price of 40.39.
CHINOOK THERAPEUTICS INC (KDNY) will report earnings on 2023-11-08, after the market close.
The consensus EPS estimate for the next earnings of CHINOOK THERAPEUTICS INC (KDNY) is -0.83 USD and the consensus revenue estimate is 255.00K USD.
The consensus rating for CHINOOK THERAPEUTICS INC (KDNY) is 72.9412 / 100 . This indicates that analysts generally have a positive outlook on the stock.